<?xml version="1.0" encoding="UTF-8"?>
<p id="p0265">Animal studies have shown that treating ACE2-knockout mice with rhuACE2 injections reduced acute lung injury resulting from acid aspiration or sepsis and improved pulmonary edema [
 <xref rid="bb0290" ref-type="bibr">57</xref>]. In a phase II clinical study, the use of rhuACE2 in 10 patients with ARDS rapidly reduced Ang II while increasing Ang 1â€“7, suggesting that ACE2 injections in humans may regulate the ACE2/ACE balance in the lungs and help to treat acute lung injury [
 <xref rid="bb0325" ref-type="bibr">64</xref>]. Recently, Monteil et al. found that human recombinant soluble ACE2 can prevent SARS-CoV-2 from infecting engineered human blood vessels and kidneys [
 <xref rid="bb0330" ref-type="bibr">65</xref>].
</p>
